<DOC>
	<DOCNO>NCT00418418</DOCNO>
	<brief_summary>This prospective double blind trial intraoperative transmyocardial bone marrowâˆ’derived mesenchymal cell transplantation v placebo patient low leave ventricular ejection fraction schedule coronary bypass operation .</brief_summary>
	<brief_title>Combined CABG Stem-Cell Transplantation Heart Failure</brief_title>
	<detailed_description>The prevalence symptomatic heart failure general population 2 % prevalence increase rapidly age . Half patient symptomatic heart failure die within 4 year diagnosis.The purpose study examine effect bone marrow-derived stem cell transplantation leave ventricular ejection fraction . Consecutive patient systolic heart failure ( n=60 ) , ischemic coronary heart disease , schedule by-pass-operation ( CABG ) collect cardiovascular laboratory outpatient clinic Helsinki University Central Hospital . Patients heart failure ejection fraction 15 45 % . Randomly patient select receive stem cell transplantation best possible heart failure medication , without cell transplantation . In study , 30 patient receive bone marrow transplantation , 30 patient serve control population . All patient receive CABG.The study carry randomize , double blind technique one year . Randomization ( block ) base table random numbers.Bone marrow patient serum blind use colored syringe , doctor transfuse sample , able know nature sample . From patient , right atrial biopsy collect assessment autologous cardiac stem cell . Also sample pericardial fluid collect measure growth factor . Comparisons : Preoperatively , patient imagine cardiac ultrasound , cardiac MRI , cardiac PET SPECT . Serum pro-BNB sample collect . Postoperatively 3 month 6 month pro-BNB cardiac ultrasound evaluate . At one year cardiac ultrasound , cardiac MRI , cardiac PET SPECT reassess . Heart failure coronary artery disease treatment beside transplantation optimize accord judgment doctor outpatients clinic . Primary endpoint study change ejection fraction MRI image .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>General ( patient must ) Symptomatic heart failure . Scheduled CABG Be 18 75 year age Informed Consent obtain Heart Failure Presentation Patients either gender , evaluate cardiovascular laboratory schedule CABG moderate heart failure , eligible NYHA IIIV symptom Left ventricular ejection fraction screen echocardiography 15 45 % . Optimal heart failure medication coronary medication operation , contain least two heart failure drug : must ACEinhibitor , AT II blocker , and/or bblocker together diuretic , digitalis aldosterone antagonist , coronary medication : statin anticoagulation , either aspirin clopidogrel . Heart failure due leave ventricular outflow track obstruction ( valve problem HOCM ) History lifethreatening ventricular arrhythmias resuscitation , condition may repeatable implanted ICD . Stroke disable condition 3 month screen Contraindications coronary angiogram MRI Other serious disease limit life expectancy Participation clinical trial Severe valve disease : mitral , aortic , tricuspid pulmonic stenosis / insufficiency Scheduled valve operation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Cell transplantation</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Clinical trial</keyword>
</DOC>